TRIBE; Tyrosine kinase inhibitor therapy in renal-cell carcinoma: Immune biomarker evaluation

被引：0
|
作者：
Villa, S. [1 ]
Pillai, M. [2 ]
Graham, D. [1 ]
Kilgour, E. [3 ]
Overton, N. [3 ]
Vasudev, N. [4 ,5 ]
Hughes, A. [6 ]
Walker, A. [1 ]
Dransfield, S. [1 ]
Thistlethwaite, F. [1 ]
机构：
[1] Christie NHS Fdn Trust, Expt Canc Med Team, Manchester, Lancs, England
[2] Christie NHS Fdn Trust, Manchester, Lancs, England
[3] Canc Res UK Manchester Inst, Clin & Expt Pharmacol Grp, Manchester, Lancs, England
[4] Leeds Inst Canc & Pathol, Leeds, W Yorkshire, England
[5] St Jamess Inst Oncol, Leeds, W Yorkshire, England
[6] Univ Manchester, Manchester, Lancs, England
来源：
ANNALS OF ONCOLOGY | 2018年 / 29卷
关键词：
D O I：
10.1093/annonc/mdy315.008
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
58TiP
引用
收藏
页码：20 / 20
页数：1
相关论文
共 50 条
  • [41] Resistance to targeted therapy in renal-cell carcinoma
    Rini, Brian I.
    Atkins, Michael B.
    LANCET ONCOLOGY, 2009, 10 (10): : 992 - 1000
  • [42] INTERFERON THERAPY FOR METASTATIC RENAL-CELL CARCINOMA
    SWANSON, DA
    QUESADA, JR
    SEMINARS IN SURGICAL ONCOLOGY, 1988, 4 (03): : 174 - 177
  • [43] SYSTEMIC THERAPY OF METASTATIC RENAL-CELL CARCINOMA
    VUGRIN, D
    SEMINARS IN NEPHROLOGY, 1987, 7 (02) : 152 - 162
  • [44] INTERFERON THERAPY IN DISSEMINATED RENAL-CELL CARCINOMA
    EDSMYR, F
    ESPOSTI, PL
    ANDERSSON, L
    STEINECK, G
    LAGERGREN, C
    STRANDER, H
    RADIOTHERAPY AND ONCOLOGY, 1985, 4 (01) : 21 - 26
  • [45] Mass cytometry-based deep immune cell profiling of metastatic clear cell renal cell carcinoma patients refractory to combined immune checkpoint and tyrosine kinase inhibitor therapy.
    Formisano, Luigi
    Belli, Stefania
    Vallefuoco, Angela
    Pecoraro, Giovanna
    Migliaccio, Fortuna
    Barraco, Chiara
    Scipilliti, Arianna
    Esposito, Daniela
    Attanasio, Giovanna
    Hameetman, Marjolijn
    Tak, Tamar
    Lopez, Ernesto
    Scagliarini, Sarah
    Servetto, Alberto
    Bianco, Roberto
    JOURNAL OF CLINICAL ONCOLOGY, 2025, 43 (5_SUPPL)
  • [46] Tyrosine kinase inhibitors in renal cell carcinoma
    Potti, A
    George, DJ
    CLINICAL CANCER RESEARCH, 2004, 10 (18) : 6371S - 6376S
  • [47] PSMD2 overexpression as a biomarker for resistance and prognosis in renal cell carcinoma treated with immune checkpoint and tyrosine kinase inhibitors
    Xu, Xianglai
    Wang, Jiahao
    Wang, Ying
    Zhu, Yanjun
    Wang, Jiajun
    Guo, Jianming
    CELLULAR ONCOLOGY, 2024, 47 (05) : 1943 - 1956
  • [48] PERIOPERATIVE IMMUNE PROFILES IN PATIENTS WITH RENAL-CELL CARCINOMA
    DANIEL, V
    POMER, S
    OPELZ, G
    DREIKORN, K
    ROHL, L
    UROLOGICAL RESEARCH, 1986, 14 (03): : 172 - 172
  • [49] Immune Checkpoint Blockade in Advanced Renal-Cell Carcinoma
    Santoni, Matteo
    Montironi, Rodolfo
    Battelli, Nicola
    NEW ENGLAND JOURNAL OF MEDICINE, 2018, 379 (01): : 91 - +
  • [50] STUDIES ON THE IMMUNE STATUS OF PATIENTS WITH RENAL-CELL CARCINOMA
    MORIYAMA, M
    KUBOTA, Y
    SHUIN, T
    NISHIMURA, R
    TAKAI, S
    JAPANESE JOURNAL OF UROLOGY, 1980, 71 (12): : 1446 - 1455
12345